Abstract

T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. In this review, we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells in fighting cancers.

Details

Title
Genetically engineered T cells for cancer immunotherapy
Author
Li, Dan 1 ; Li, Xue 1 ; Wei-Lin, Zhou 1 ; Huang, Yong 1 ; Liang, Xiao 2 ; Jiang, Lin 1 ; Yang, Xiao 1 ; Sun, Jie 3 ; Li, Zonghai 4 ; Wei-Dong, Han 5 ; Wang, Wei 1   VIAFID ORCID Logo 

1  Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and the Collaborative Innovation Center for Biotherapy, Chengdu, China 
2  Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and the Collaborative Innovation Center for Biotherapy, Chengdu, China; Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, and the Collaborative Innovation Center for Biotherapy, Chengdu, China 
3  Department of Cell Biology, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China; Institute of Hematology, Zhejiang University & Laboratory of Stem cell and Immunotherapy Engineering, Zhejing, China 
4  State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; CARsgen Therapeutics, Shanghai, China 
5  Molecular & Immunological Department, Biotherapeutic Department, Chinese PLA General Hospital, Beijing, China 
Pages
1-17
Publication year
2019
Publication date
Sep 2019
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41392-019-0070-9
ProQuest document ID
2293862139
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.